Article
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.
Leukemia - 1 Aug 2016
Chaturvedi A, Araujo Cruz M M, Jyotsana N, Sharma A, Goparaju R, Schwarzer A, Görlich K, Schottmann R, Struys E A, Jansen E E, Rohde C, Müller-Tidow C, Geffers R, Göhring G, Ganser A, Thol F, Heuser M
Abstract excerpt
Canonical mutations in IDH1 and IDH2 produce high levels of the R-enantiomer of 2-hydroxyglutarate (R-2HG), which is a competitive inhibitor of α-ketoglutarate (αKG)-dependent enzymes and a putative oncometabolite. Mutant IDH1 collaborates with HoxA9 to induce monocytic leukemia in vivo. We used two mouse models and a patient-derived acute myeloid leukemia xenotransplantation (PDX) model to evaluate the in vivo...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.